The seventh wave of the Covid-19 epidemic is barely over the government already fears the eighth for the start of the school year ! To deal with it, he could extend the second booster dose to all. This is currently recommended for people over 60, vulnerable and immunocompromised people (and those living alongside them), pregnant women, but also healthcare professionals and employees in the medico-social sector.
Anti-covid vaccine: 4 new products expected in France
To organize its future coronavirus vaccination campaign next fall, the government is banking on four new products: a Spanish vaccine, a new vaccine from Pfizer/BioNTech and Moderna adapted to Omicron, and a vaccine from Sanofi.
The Moderna and Pfizer/BioNTech vaccines will still be messenger RNA, but in addition to the original strain of the Sars-Cov-2 virus, they will be made with the Omicron variant as well. These two new serums are currently being assessed by the European Medicines Agency (EMA) in order to obtain marketing authorisation.
Covid-19: the arrival of a French vaccine on the market?
Another highly anticipated vaccine this fall: that of the French pharmaceutical group Sanofi. The company has developed a recombinant protein vaccine with adjuvant (conventional vaccine), made from the original strain of the Wuhan virus and the Beta variant.
In a press release dated June 24, Sanofi states that the tests showed that a booster dose of this vaccine was 72% effective (confidence interval between 45.8 and 86.6%) against symptomatic forms with the Omicron variant. A protection that would amount to 93.2% (confidence interval between 73.2% and 99.2%) in people who have already had Covid and therefore benefit from so-called “natural” immunity.
However, this study was not conducted on the BA.5 sub-lineage of the Omicron variant which is now ultra-majority in France. But the company wants to be reassuring, saying that efficacy of current vaccines appears similar against all Omicron variants. A marketing application was made to the EMA last March.
What is this new Spanish Covid vaccine?
The Spanish laboratory Hipra has also developed a recombinant protein vaccine against Sars-CoV-2 virus. This was designed from Alpha and Beta strains of the virus.
In a press release from last July, the company claims that a “increase in neutralizing antibodies against Omicron BA.2, BA.4 and BA.5 was observed 14 days after administration of the vaccine as a booster dose in participants previously vaccinated with two doses of the Pfizer/BioNTech vaccine”. An effect also observed on the group of volunteers initially vaccinated with Moderna’s messenger RNA vaccine. However, no details regarding this efficacy have been reported.
This vaccine has not yet received marketing authorization from the EMA, but the European Commission has already announced, on Tuesday August 2, that it has signed an agreement allowing it to acquire nearly 250,000 doses.